LITERATURE - calprotectin

Key publications on circulating calprotectin

Here you will find recommended reading list of key publications on plasma and serum calprotectin as biomarker in selected clinical applications. The listed publications should only be used as general information to accumulate selected publications covering calprotectin.

If you want more comprehensive lists of publications and studies on calprotectin across various disease areas, kindly get in touch with us via marketing@gentian.com.

 

Literature lists

Rheumatoid Arthritis (RA)

Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: a 5 year follow-up study. Ramírez J, et al. Rheumatology (Oxford). 2021 Feb. PMID: 32653929

Circulating Calprotectin (cCLP) in autoimmune diseases. Manfredi M, et al. Autoimmun Rev. 2023 May. PMID: 36781037

Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: a meta-analysis. Zeng J, et al. Biomark Med. 2022 Dec. PMID: 36661047

From to bedside: Calprotectin (S100A8/S100A9) as a biomarker in rheumatoid arthritis. Inciarte-Mundo J, et al. Front Immunol. 2022 Nov. PMID: 36405711

Calprotectin tracks tocilizumab-treated RA. Onuora S. Nat Rev Rheumatol. 2022 Nov. PMID: 36163436

Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors. Frade-Sosa B, et al. Ther Adv Musculoskelet Dis. 2022 Sep. PMID: 36148395

Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy. Gernert M, Set al. Arthritis Res Ther. 2022 Aug. PMID: 35986420

Serum Calprotectin is Indicating Clinical and Ultrasonographic Disease Activity in Rheumatoid Arthritis, even with Normal C-Reactive Protein Levels. Torgutalp M, et al. Mediterr J Rheumatol. 2021 Feb. PMID: 34386702

Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Jarlborg M, et al. Arthritis Res Ther. 2020 May. PMID: 32375861

Systemic calprotectin and chronic inflammatory rheumatic diseases. Romand X, et al. Joint Bone Spine. 2019 Nov. PMID: 30660804

A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients With Rheumatoid Arthritis. Bach M,  et al. Arthritis Rheumatol. 2020. PMID: 31353807

The Role of Calprotectin in Rheumatoid Arthritis. Wang Q, et al. J Transl Int Med. 2019 Dec. PMID: 32010597

Clinical significance of serum calprotectin level for the disease activity in active rheumatoid arthritis with normal C-reactive protein. Wang Y, Liang Y. Int J Clin Exp Pathol. 2019 Mar. PMID: 31933912

Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. Inciarte-Mundo J, et al. Arthritis Res Ther. 2018 Dec. PMID: 30545393

Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein. Hurnakova J, et al. Clin Rheumatol. 2018 Aug. PMID: 29656372

Calprotectin in patients with chronic rheumatoid arthritis correlates with disease activity and responsiveness to methotrexate. Nielsen UB, et al. Scand J Clin Lab Invest. 2018 Feb-Apr. PMID: 29228799

Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. Hurnakova J, et al. PLoS One. 2017 Aug. PMID: 28832684

Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. Bae SC, Lee YH. Postgrad Med. 2017 Jun. PMID: 28425837

Calprotectin in rheumatic diseases. Ometto F, et al. Exp Biol Med (Maywood). 2017 Apr. PMID: 27895095

Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis. Nordal HH, et al. Arthritis Res Ther. 2017 Jan. PMID: 28081709

Calprotectin in rheumatic diseases: a review. Kopeć-Mędrek M, et al. Reumatologia. 2016. PMID: 28115781

S100A8/A9: From basic science to clinical application. Pruenster M, et al. Pharmacol Ther. 2016. PMID: 27492899

Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. Hurnakova J, et al. PLoS One. 2016 Nov. PMID: 27832086

Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. Inciarte-Mundo J, et al. Arthritis Care Res (Hoboken). 2016. PMID: 26841119

Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Inciarte-Mundo J, et a. Rheumatology (Oxford). 2015 Dec. PMID: 26242859

Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. Abildtrup M, et al. J Rheumatol. 2015 May. PMID: 25729036

S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis. Kang KY, et al. Korean J Intern Med. 2014. PMID: 24574827

Alarmins: awaiting a clinical response. Chan JK, et al. J Clin Invest. 2012 Aug. PMID: 22850880

Juvenile Idiopathic Arthritis (JIA)

Serum calprotectin and joint ultrasound in the definition of disease relapse in non-systemic juvenile idiopathic arthritis: a prospective longitudinal study. d'Angelo DM, et al. Clin Exp Rheumatol. 2023 Oct. PMID: 37877377.

Use of MRP8/14 in clinical practice as a predictor of outcome after methotrexate withdrawal in patients with juvenile idiopathic arthritis. Sumner EJ, et al. Clin Rheumatol. 2022 Sep. PMID: 35486225

Myeloid-related protein 8/14 in plasma and serum in patients with new-onset juvenile idiopathic arthritis in real-world setting in a single center. Keskitalo PL, et al. Pediatr Rheumatol Online J. 2022 Jun. PMID: 35710418

Serum Calprotectin a Potential Biomarker in Juvenile Idiopathic Arthritis: A Meta-Analysis. Altobelli E, et al. J Clin Med. 2021 Oct. PMID: 34768386

Serum calprotectin (S100A8/A9): a promising biomarker in diagnosis and follow-up in different subgroups of juvenile idiopathic arthritis. La C, et al. RMD Open. 2021. PMID: 34108235

Systemic calprotectin and chronic inflammatory rheumatic diseases. Romand X, et al. Joint Bone Spine. 2019 Nov. PMID: 30660804

Alarmins of the S100-Family in Juvenile Autoimmune and Auto-Inflammatory Diseases. Holzinger D, et al. Front Immunol. 2019 Feb. PMID: 30828327 

The role of S100 proteins in the pathogenesis and monitoring of autoinflammatory diseases. Holzinger D, et al. Mol Cell Pediatr. 2018 Sep. PMID: 30255357

Calprotectin in rheumatic diseases. Ometto F, et al. Exp Biol Med (Maywood). 2017 Apr. PMID: 27895095

Calprotectin in rheumatic diseases: a review. Kopeć-Mędrek M, et al. Reumatologia. 2016. PMID: 28115781

S100A8/A9: From basic science to clinical application. Pruenster M, et al. Pharmacol Ther. 2016. PMID: 27492899

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Anink J, et al. Arthritis Res Ther. 2015 Aug. PMID: 26249667

A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Moncrieffe H, et al. Rheumatology (Oxford). 2013 Aug. PMID: 23620557

Alarmins: awaiting a clinical response. Chan JK, et al. J Clin Invest. 2012 Aug. PMID: 22850880

Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. Foell D, et al. JAMA. 2010 Apr. PMID: 20371785

Myeloid related proteins MRP8/MRP14 may predict disease flares in juvenile idiopathic arthritis. Schulze zur Wiesch A, et al. Clin Exp Rheumatol. 2004 May-Jun. PMID: 15144135

Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? Foell D, et al. Ann Rheum Dis. 2004 Feb. PMID: 14722212

Still's disease (sJIA and AOSD)

MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. Park C, et al. Rheumatology (Oxford). 2022 Jul. PMID: 34559193

Serum Calprotectin a Potential Biomarker in Juvenile Idiopathic Arthritis: A Meta-Analysis. Altobelli E, et al. J Clin Med. 2021 Oct. PMID: 34768386

The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Aljaberi N, et al. Pediatr Rheumatol Online J. 2020 Jan. PMID: 31948488

Systemic calprotectin and chronic inflammatory rheumatic diseases. Romand X, et al. Joint Bone Spine. 2019 Nov. PMID: 30660804

Alarmins of the S100-Family in Juvenile Autoimmune and Auto-Inflammatory Diseases. Holzinger D, et al. Front Immunol. 2019 Feb. PMID: 30828327 

The role of S100 proteins in the pathogenesis and monitoring of autoinflammatory diseases. Holzinger D, et al. Mol Cell Pediatr. 2018 Sep. PMID: 30255357

Calprotectin in rheumatic diseases. Ometto F, et al. Exp Biol Med (Maywood). 2017 Apr. PMID: 27895095

Measurement of blood calprotectin (MRP-8/MRP-14) levels in patients with juvenile idiopathic arthritis. Bojko J. Reumatologia. 2017 Mar. PMID: 28386137

Calprotectin in rheumatic diseases: a review. Kopeć-Mędrek M, et al. Reumatologia. 2016. PMID: 28115781

Serum calprotectin-a promising diagnostic marker for adult-onset Still's disease. Guo Q, et al. Clin Rheumatol. 2016 Jan. PMID: 26547221

S100A8/A9: From basic science to clinical application. Pruenster M, et al. Pharmacol Ther. 2016. PMID: 27492899

Alarmins: awaiting a clinical response. Chan JK, et al. J Clin Invest. 2012 Aug. PMID: 22850880

Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease. Kim HA, et al. J Rheumatol. 2012 Jul. PMID: 22660800.

The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Holzinger D, et al. Ann Rheum Dis. 2012 Jun. PMID: 22267331

The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Frosch M, et al. Arthritis Rheum. 2009 Mar. PMID: 19248102.

Bacterial infections and sepsis

Blood calprotectin as a biomarker for infection and sepsis - the prospective CASCADE trial. Diehl-Wiesenecker E, et al.  BMC Infect Dis. 2024 May  PMID: 38755564

Validation of Serum Calprotectin Relative to Other Biomarkers of Infection in Febrile Infants Presenting to the Emergency Department. Bohn MK, et al.  Antibiotics. 2024 May

Roles of S100A8, S100A9 and S100A12 in infection, inflammation and immunity. Xia P, et al. Immunology. 2023 Nov. PMID: 38013255

S100A8/A9: An emerging player in sepsis and sepsis-induced organ injury. Wang Q, et al. Biomed Pharmacother. 2023 Oct. PMID: 37812889

Therapeutic S100A8/A9 blockade inhibits myocardial and systemic inflammation and mitigates sepsis-induced myocardial dysfunction. Jakobsson G, et al. Crit Care. 2023 Sep. PMID: 37773186

Analysis of Calprotectin as an Early Marker of Infections Is Economically Advantageous in Intensive Care-Treated Patients. Havelka A, et al. Biomedicines. 2023 Aug. PMID: 37626653

Serum level of S100A8/A9 as a biomarker for establishing the diagnosis and severity of community-acquired pneumonia in children. Xie S, et al. Front Cell Infect Microbiol. 2023 Apr. PMID: 37180431

Novel mechanisms of thrombo-inflammation during infection: spotlight on neutrophil extracellular trap-mediated platelet activation. Colicchia M, et al. Res Pract Thromb Haemost. 2023 Mar. PMID: 37063765

Plasma calprotectin as an indicator of need of transfer to intensive care in patients with suspected sepsis at the emergency department. Parke Å, et al. BMC Emerg Med. 2023 Feb. PMID: 36774492

Calprotectin as a diagnostic marker for sepsis: A meta-analysis. Gao RY, et al. Front Cell Infect Microbiol. 2022 Nov. PMID: 36519133

Serum Calprotectin Is a Valid Biomarker in Distinction of Bacterial Urinary Tract Infection From Viral Respiratory Illness in Children Under 3 Years of Age. Lamot M, et al. Front Pediatr. 2022 Mar. PMID: 35359908

Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients. Wirtz TH, Bet al. Diagnostics (Basel). 2020 Nov. PMID: 33238644

Kinetics of calprotectin, procalcitonin and C-reactive protein in healthy volunteers administered intravenous endotoxin. Fullerton JN, et al. 40th International Symposium on Intensive Care & Emergency Medicine. Crit Care 24, 87 (2020). Abstract No: P474

Calprotectin, a new biomarker for diagnosis of acute respiratory infections. Havelka A, et al. Sci Rep. 2020 Mar. PMID: 32144345

Calprotectin is superior to procalcitonin as a sepsis marker and predictor of 30-day mortality in intensive care patients. Larsson A,et al. Scand J Clin Lab Invest. 2020. PMID: 31841042

High plasma level of S100A8/S100A9 and S100A12 at admission indicates a higher risk of death in septic shock patients. Dubois C, et al. Sci Rep. 2019. PMID: 31666644

Calprotectin and calgranulin C serum levels in bacterial sepsis. Bartáková E, et al. Diagn Microbiol Infect Dis. 2019 Mar. PMID: 30420210

Inflammatory biomarkers are associated with aetiology and predict outcomes in community-acquired pneumonia: results of a 5-year follow-up cohort study. Siljan WW, et al. ERJ Open Res. 2019 Mar. PMID: 30863773.

Calprotectin as an early biomarker of bacterial infections in critically ill patients: an exploratory cohort assessment. Jonsson N, et al. Crit Care Resusc. 2017 Sep. PMID: 28866970

Serum Calprotectin Expression as a Diagnostic Marker for Sepsis in Postoperative Intensive Care Unit Patients. Huang L, et al. J Interferon Cytokine Res. 2016. PMID: 27610929

Diagnostic and prognostic value of myeloid-related protein complex 8/14 for sepsis. Gao S, et al. Am J Emerg Med. 2015 Sep. PMID: 26206243

COVID-19

Elevated level of circulating calprotectin correlates with severity and high mortality in patients with COVID-19. Zhang H, et al. Immun Inflamm Dis. 2024 Mar. PMID: 38477671

Calprotectin serum levels on admission and during follow-up predict severity and outcome of patients with COVID-19: A prospective study. Gatselis NK, et al. Eur J Intern Med. 2023 Nov. PMID: 37953124.

Serum calprotectin can indicate current and future severity of COVID-19. Shokri-Afra H, et al. J Clin Lab Anal. 2023 Jan. PMID: 36525302

Serial measurement of circulating calprotectin as a prognostic biomarker in COVID-19 patients in intensive care setting. Nevejan L, et al. Clin Chem Lab Med. 2022 Dec. PMID: 36473060.

Clinical utility of circulating calprotectin to assist prediction and monitoring of COVID-19 severity: An Italian study Infantino M, et al. J Med Virol. 2022 Aug. PMID: 35941084

Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients. Chapuis N, et al. EBioMedicine. 2022 Jun. PMID: 35644124

Circulating Calprotectin as a Predictive and Severity Biomarker in Patients with COVID-19. Norman GL, et al. Diagnostics (Basel). 2022 May. PMID: 35741134

A meta-analysis of the association between calprotectin and the severity of COVID-19. Mao Q, et al. J Infect. 2022 Mar. PMID: 35074506

S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes. Mellett L, Khader SA. Cytokine Growth Factor Rev. 2022 Feb. PMID: 34728150

Circulating levels of calprotectin, a signature of neutrophil activation in prediction of severe respiratory failure in COVID-19 patients: a multicenter, prospective study (CalCov study). de Guadiana-Romualdo L, et al. Inflamm Res. 2021 Oct. PMID: 34718856

S100A8 may govern hyper-inflammation in severe COVID-19. Deguchi A, et al. FASEB J. 2021 Sep. PMID: 34339064.

Calprotectin and SARS-CoV-2: A Brief-Report of the Current Literature. Giuffrè M,  et al. Healthcare (Basel). 2021 Aug. PMID: 34442092

Oxidative Stress and Inflammatory Biomarkers for the Prediction of Severity and ICU Admission in Unselected Patients Hospitalized with COVID-19. Ducastel M, et al. Int J Mol Sci. 2021 Jul. PMID: 34299080.

Circulating Calprotectin as a Biomarker of COVID-19 Severity. Mahler M, et al. Expert Rev Clin Immunol. 2021 Mar. PMID: 33750254.

Calprotectin, an Emerging Biomarker of Interest in COVID-19: A Systematic Review and Meta-Analysis. Udeh R, et al. J. Clin. Med. 2021 Feb. PMID: 33672040

The Inflammatory Factors Associated with Disease Severity to Predict COVID-19. Huang W, Li et al. Progression. J Immunol. 2021 Feb. PMID: 33579725.

Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Guo Q, et al. Cell Host Microbe. 2020 Dec. PMID: 33388094

Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department. Bauer W, et al. J Infect. 2020 Nov. PMID: 33217473

COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis. Sohn KM, et al. J Korean Med Sci. 2020 Sep. PMID: 32989935

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Silvin A, et al. Cell. 2020 Sep. PMID: 32810439

Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Chen L, et al. Cell Mol Immunol. 2020 Sep. PMID: 32620787

Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. Shi H, et al. J Leukoc Biol. 2020 Sep. PMID: 32869342

Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: A case series. de Guadiana Romualdo LG, et al. J Infect. 2020 Aug. PMID: 32795482

gcal validation kit

Get in touch

GCAL® is applied to turbidimetry-based clinical chemistry platforms. It is an open channel assay, meaning it can be added to all clinical chemistry analysers.

  • CE-marked and IVDR certified
  • Developed and manufactured by Gentian
  • Manufactured according to ISO 13485:2016

Explore GCAL® in your laboratory - fill out the form below or send an email to marketing@gentian.com for more information about the product and prices.

 

 

This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances.